Drug IndexKymriah (tisagenlecleucel)
Billing
Code: Q2042
Description: Tisagenlecleucel car-pos t
Unit: N/A
Payment: $518240.680
Pay quarter: Q2 2024
Covered in Part D: No
Drug Cost
Calculate drug cost and reimbursement
Total WAC:
$543,827.50Total Reimbursement:
$∞(ASP: $∞, Margin: $∞)
.
.# Units to bill:
InfinityDosage & Frequency
B-cell precursor acute lymphoblastic leukemia (ALL)
• 0.2 to 5.0 x 10^6 CAR-positive viable T cells per kg IV if patient weighs 50kg or below
• 0.1 to 2.5 x 10^8 CAR-positive viable T cells IV if patient weighs above 50kg
• 0.2 to 5.0 x 10^6 CAR-positive viable T cells per kg IV if patient weighs 50kg or below
• 0.1 to 2.5 x 10^8 CAR-positive viable T cells IV if patient weighs above 50kg
Billable NDCs
00078-0846-19
Kymriah (pediatric dose) (NOVARTIS PHARMACEUTICALS CORPORATION)
0 up to 600 million CAR-positive viable T cells
00078-0958-19
Kymriah (adult dose) (NOVARTIS PHARMACEUTICALS CORPORATION)
0 up to 600 million CAR-positive viable T cells
Resources